For the quarter ending 2025-03-31, NKGN has $15,842K in assets. $66,174K in debts. $6K in cash and cash equivalents.
| Balance Sheets | 2025-03-31 | |||
|---|---|---|---|---|
| Cash and cash equivalents | 6 | |||
| Restricted cash | 23 | |||
| Prepaid expenses and other current assets | 2,352 | |||
| Total current assets | 2,381 | |||
| Property and equipment, net | 13,024 | |||
| Operating lease right-of-use asset, net | 341 | |||
| Capitalized software, net | 96 | |||
| Total assets | 15,842 | |||
| Accounts payable and accrued expenses | 16,738 | |||
| Forward purchase derivative liabilities | 175 | |||
| Convertible debt-Promissory Notes | 18,303 | |||
| Related party loans | 4,000 | |||
| Revolving line of credit | 4,257 | |||
| Operating lease liability, current | 154 | |||
| Convertible debt-Bridge Loan | 196 | |||
| Other current liabilities | 65 | |||
| Total current liabilities | 43,888 | |||
| Derivative warrant liabilities | 10,995 | |||
| Senior convertible promissory notes, due to related parties | 11,077 | |||
| Operating lease liability, non-current | 206 | |||
| Deferred tax liabilities | 8 | |||
| Total liabilities | 66,174 | |||
| Common stock, 0.0001 par value 500,000,000 authorized shares as of march31, 2025 and december31, 2024 51,306,712 and 44,238,754 shares issued and outstanding as of march31, 2025 and december31, 2024, respectively | 5 | |||
| Additional paid-in capital | 140,911 | |||
| Subscription receivable | 182 | |||
| Accumulated deficit | -191,066 | |||
| Total stockholders deficit | -50,332 | |||
| Total liabilities and stockholders deficit | 15,842 | |||
NKGen Biotech, Inc. (NKGN)
NKGen Biotech, Inc. (NKGN)